INT12992

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1987
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 33
Total Number 34
Disease Relevance 20.47
Pain Relevance 11.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (Ptgs1) aging (Ptgs1) Golgi apparatus (Ptgs1)
endoplasmic reticulum (Ptgs1) cytoplasm (Ptgs1) lipid binding (Ptgs1)
Anatomy Link Frequency
paw 4
macrophages 2
monocyte 2
neurons 2
temporomandibular joint 2
Ptgs1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
aspirin 42 100.00 Very High Very High Very High
COX-2 inhibitor 14 100.00 Very High Very High Very High
Analgesic 12 100.00 Very High Very High Very High
COX2 11 100.00 Very High Very High Very High
diclofenac 4 100.00 Very High Very High Very High
agonist 2 100.00 Very High Very High Very High
cINOD 65 99.92 Very High Very High Very High
withdrawal 7 99.74 Very High Very High Very High
electroacupuncture 9 99.64 Very High Very High Very High
Inflammation 92 99.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Adhesions 67 100.00 Very High Very High Very High
Cancer 19 100.00 Very High Very High Very High
Necrosis 7 100.00 Very High Very High Very High
Fever 1 99.68 Very High Very High Very High
INFLAMMATION 133 99.52 Very High Very High Very High
Adenocarcinoma 3 99.40 Very High Very High Very High
Adverse Drug Reaction 1 98.40 Very High Very High Very High
Anaphylaxis 10 98.24 Very High Very High Very High
Rheumatoid Arthritis 13 98.20 Very High Very High Very High
Toxicity 4 97.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Gene_expression (selective) of cyclooxygenase
1) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Gene_expression (selective) of cyclooxygenase-1
2) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Gene_expression (selective) of cyclooxygenase
3) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
Therefore, the antiinflammatory activity of guanabenz may be due to its ability to inhibit the formation of 5-lipoxygenase and cyclooxygenase products.
Negative_regulation (inhibit) of Gene_expression (products) of cyclooxygenase associated with inflammation
4) Confidence 0.37 Published 1987 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3121363 Disease Relevance 0.75 Pain Relevance 0.22
The use of nonsteroidal antiinflammatory drugs (NSAID) in patients with these conditions can produce a significant decline in renal function, including decreased glomerular filtration rate and solute and water excretion, by inhibiting renal cyclooxygenase, and thus, PG production.
Negative_regulation (inhibiting) of Gene_expression (production) of cyclooxygenase associated with inflammation and cinod
5) Confidence 0.34 Published 1991 Journal J Rheumatol Suppl Section Abstract Doc Link 1903810 Disease Relevance 0.26 Pain Relevance 0.26
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Negative_regulation (inhibition) of Gene_expression (expression) of cyclooxygenase associated with adenocarcinoma
6) Confidence 0.32 Published 1999 Journal Anticancer Res. Section Title Doc Link 10697514 Disease Relevance 0.41 Pain Relevance 0.12
To investigate the hypothesis that the gastric damage caused by NSAIDs is due not only to the decreased level of cyclooxygenase products but to the increased level of lipoxygenase products as well, different lipoxygenase inhibitors and leukotriene antagonists were tested.
Negative_regulation (decreased) of Gene_expression (products) of cyclooxygenase associated with antagonist and cinod
7) Confidence 0.32 Published 1993 Journal Arzneimittelforschung Section Abstract Doc Link 8369011 Disease Relevance 0.22 Pain Relevance 0.36
This is achieved through inhibition of prostaglandin endoperoxide synthase (PGHS) or cyclooxygenase (COX) synthesis.
Negative_regulation (inhibition) of Gene_expression (synthesis) of prostaglandin endoperoxide synthase
8) Confidence 0.28 Published 2000 Journal Rev Med Interne Section Abstract Doc Link 10763201 Disease Relevance 0.30 Pain Relevance 0.43
Moreover, angiotensin II selectively increased cardiac cyclooxygenase-2 but not cyclooxygenase-1 expression, which was totally prevented by acetylsalicylic acid treatment.
Negative_regulation (prevented) of Gene_expression (expression) of cyclooxygenase-1 associated with aspirin
9) Confidence 0.25 Published 2005 Journal Hypertension Section Abstract Doc Link 15851630 Disease Relevance 0.93 Pain Relevance 0.24
As a result of the ability of NSAIDs to block the enzymatic activity of cyclooxygenase, and therefore, the production of prostaglandins, prostacyclin, and thromboxanes, they have analgesic, antiinflammatory, and antipyretic properties.[3233] Piroxicam is an effective antiinflammatory agent; it is about equal to indomethacin in potency as an inhibitor of prostaglandin biosynthesis in vitro.
Negative_regulation (block) of Gene_expression (production) of cyclooxygenase associated with inflammation, analgesic, cinod and potency
10) Confidence 0.23 Published 2008 Journal Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association Section Body Doc Link PMC2702925 Disease Relevance 1.11 Pain Relevance 0.53
Aspirin, sodium salicylate, dipyrone (100 mg/kg each) and indomethacin (2 and 20 mg/kg) decrease the concentrations of cyclooxygenase products of arachidonate metabolism, but did not significantly affect levels of 15-HETE.
Negative_regulation (decrease) of Gene_expression (products) of cyclooxygenase associated with aspirin
11) Confidence 0.21 Published 1991 Journal Agents Actions Section Abstract Doc Link 1659153 Disease Relevance 0.30 Pain Relevance 0.43
Administration of EGF was able to: (i) reduce cyclooxygenase expression in the uterus (determined by western blot analysis) and production of prostaglandins by the uterus (evaluated by conversion of [(14)C]arachidonate to labelled prostaglandins); (ii) decrease prostaglandin concentrations in amniotic fluid (radioimmunoassay); (iii) increase NO production (evaluated by conversion of [(14)C]arginine into [(14)C]citrulline); (iv) increase serum progesterone concentrations to more than control concentrations (P<0.05; radioimmunoassay); and (v) reduce the amplitude of the uterine contractions.
Negative_regulation (reduce) of Gene_expression (expression) of cyclooxygenase in uterine associated with dismenorea
12) Confidence 0.17 Published 2003 Journal Reproduction Section Abstract Doc Link 14525528 Disease Relevance 0.15 Pain Relevance 0.15
The expression of cyclooxygenase (COX)-1, COX-2, and inducible nitric oxide synthase (iNOS) was inhibited by 2 Hz EA in carrageenan-injected rat paws.
Negative_regulation (inhibited) of Gene_expression (expression) of cyclooxygenase associated with electroacupuncture
13) Confidence 0.17 Published 2006 Journal Am. J. Chin. Med. Section Abstract Doc Link 17163587 Disease Relevance 1.09 Pain Relevance 0.94
Six major groups of rats with gastric ulcers were used: (1) vehicle (saline); (2) streptozotocin alone; (3) insulin (4 IU/day intraperitoneally); (4) streptozotocin plus insulin; (5) pentoxifylline, an inhibitor of synthesis and release of tumor necrosis factor-alpha (TNF alpha); and (6) aspirin, a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), and rofecoxib, the highly selective COX-2.
Negative_regulation (inhibitor) of Gene_expression (synthesis) of cyclooxygenase-1 associated with aspirin, necrosis, cancer and peptic ulcer
14) Confidence 0.17 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14642793 Disease Relevance 1.36 Pain Relevance 0.09
Six major groups of rats with gastric ulcers were used: (1) vehicle (saline); (2) streptozotocin alone; (3) insulin (4 IU/day intraperitoneally); (4) streptozotocin plus insulin; (5) pentoxifylline, an inhibitor of synthesis and release of tumor necrosis factor-alpha (TNF alpha); and (6) aspirin, a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), and rofecoxib, the highly selective COX-2.
Negative_regulation (inhibitor) of Gene_expression (synthesis) of cyclooxygenase-1 associated with aspirin, necrosis, cancer and peptic ulcer
15) Confidence 0.17 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14642793 Disease Relevance 1.36 Pain Relevance 0.09
SK&F 105809 was determined to be a prodrug for the sulfide metabolite SK&F 105561 which is an inhibitor of 5-lipoxygenase (5-LO) and prostaglandin H (PGH) synthase activities seen with both the isolated enzyme (IC50S 3 microM) and human monocyte production of the eicosanoids leukotriene B4 (LTB4, IC50 1.0 microM) and prostaglandin E2 (PGE2, IC50 0.1 microM).
Negative_regulation (inhibitor) of Gene_expression (synthase) of PGH in monocyte
16) Confidence 0.16 Published 1990 Journal Drugs Exp Clin Res Section Abstract Doc Link 2127565 Disease Relevance 0.44 Pain Relevance 0.14
Nonsteroidal anti-inflammatory drugs can impair renal perfusion through inhibition of cyclooxygenase (COX)-mediated prostaglandin synthesis.
Negative_regulation (inhibition) of Gene_expression (synthesis) of cyclooxygenase associated with inflammation and cinod
17) Confidence 0.16 Published 2000 Journal Exp. Nephrol. Section Abstract Doc Link 10810234 Disease Relevance 0.10 Pain Relevance 0.18
The TNF-alpha (10 pg)-induced reduction in paw withdrawal latency was blocked by simultaneous injection of diclofenac (1 ng), a cyclooxygenase inhibitor, or interleukin-1 receptor antagonist (IL-1 ra, 10 ng).
Negative_regulation (blocked) of Gene_expression (injection) of cyclooxygenase in paw associated with antagonist, rheumatoid arthritis, diclofenac and withdrawal
18) Confidence 0.10 Published 1996 Journal Neuroimmunomodulation Section Abstract Doc Link 8945729 Disease Relevance 1.16 Pain Relevance 0.55
The TNF-alpha (10 pg)-induced reduction in paw withdrawal latency was blocked by simultaneous injection of diclofenac (1 ng), a cyclooxygenase inhibitor, or interleukin-1 receptor antagonist (IL-1 ra, 10 ng).
Negative_regulation (inhibitor) of Gene_expression (injection) of cyclooxygenase in paw associated with antagonist, rheumatoid arthritis, diclofenac and withdrawal
19) Confidence 0.10 Published 1996 Journal Neuroimmunomodulation Section Abstract Doc Link 8945729 Disease Relevance 1.16 Pain Relevance 0.55
Evaluation of 5-LOX metabolites-by LC/MS/MS and ELISA confirmed that both compounds selectively inhibited all products downstream of 5-hydroperoxy eicosatetraenoic acid (5-HPETE), including 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxoETE), without inhibition of 12-lipoxygenase (12-LOX), 15-lipoxygenase (15-LOX), or cyclooxygenase (COX) products.
Negative_regulation (inhibition) of Gene_expression (products) of cyclooxygenase
20) Confidence 0.08 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18295198 Disease Relevance 0.05 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox